|
|
Vol. 15.20 – 13 August, 2024
|
|
|
|
|
|
|
|
Large-scale sequencing of OPRD1 and in vitro analysis revealed that loss-of-function variants were associated with higher adiposity and lower hyperglycemia risk, whereas gain-of-function variants were associated with lower adiposity and higher type 2 diabetes risk.
[Nature Communications]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
|
|
Neuroplastin (NPTN) deficiency improved glucose tolerance by increasing insulin secretion and β cell mass in the pancreas. Proliferation and mitochondrial numbers in β cells increased in Nptn knockout islets.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
The authors revealed that dexamethasone significantly increased apoptosis in INS-1 cells when compared to the control, and that imatinib significantly decreased INS-1 cell apoptosis induced by dexamethasone.
[Scientific Reports]
|
|
|
|
|
|
|
|
Upstream frameshift 1 (Upf1) helicase deficiency led to increased mitochondrial complex I activity which produced reactive oxygen species (ROS) that signaled for cytokine release that drove immune suppression and enhanced pancreatic tumor growth.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
Researchers found a super-enhancer enriched with abnormally active histone modifications in PDAC, called DKK1-super-enhancer (DKK1-SE). Mechanistically, AP1 induced chromatin remodeling in component enhancer e1 and activated the transcriptional activity of DKK1.
[Cell Death & Disease]
|
|
|
|
|
|
Investigators demonstrated that inositol polyphosphate 4-phosphatase, type II (INPP4B) overexpression in PDAC was associated with PDAC progression. INPP4B overexpression promoted peripheral dispersion and exocytosis of lysosomes resulting in increased migratory and invasive potential of PDAC cells.
[Journal of Cell Biology]
|
|
|
|
|
|
|
|
Scientists discuss current thinking and areas of debate around intra-islet connectivity, cellular hierarchies, and potential “controlling” beta-cell populations. They focus on methodologies, including comparisons of different cell preparations as well as in vitro and in vivo approaches to imaging.
[Nature Metabolism]
|
|
|
|
|
|
A more comprehensive and in-depth understanding of the metabolic regulation of pancreatic cancer cells will not only enrich the understanding of the mechanisms of disease progression, but also provide inspiration for new diagnostic and therapeutic approaches.
[Cell Death & Disease]
|
|
|
|
|
|
|
|
PanTher Therapeutics, Inc. announced the US FDA clearance of the Investigational New Drug application for the company’s lead program, PTM-101, to proceed in a Phase IB clinical study in patients with PDAC.
[PanTher Therapeutics, Inc. (BusinessWire, Inc)]
|
|
|
|
|
|
|
|
September 6-9, 2024
Breckenridge, Colorado, United States
|
|
|
|
|
|
|
|
|
|
|
San Diego Biomedical Research Institute – San Diego, California, United States
|
|
|
|
|
|
|
City of Hope – Monrovia, California, United States
|
|
|
|
|
|
|
|
|
University of Hong Kong – Hong Kong, Hong Kong
|
|
|
|
|
|
|
University of Michigan – Ann Arbor, Michigan, United States
|
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
